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Summary 
The self-mouse lysozyme peptide corresponding to residues 46-62 (ML46-62) binds to the major 
histocompatibility complex (MHC)  class II molecules I-A  k and it  selectively inhibits, when 
coinjected with antigen, priming of I-Ak-restricted, antigen-specific  T  cells. We demonstrate 
that  administration of ML46-62  also  inhibits in vivo antibody responses  induced by I-A  k- 
restricted T helper cells. ML46-62 is able to prevent the primary anti-hen egg white lysozyme 
(HEL) antibody response induced by the entire HEL molecule in B10.A(4R) mice, expressing 
only I-A  k molecules, but not in mice of H-2  a haplotype. ML46-62 also strongly decreases, in 
B10.A(4R) mice, the antibody response to ribonuclease  A, a protein antigen unrelated to the 
MHC blocker, indicating that MHC blockade is the mechanism leading to inhibition of antibody 
response. This is further supported by the concomitant decrease, in vivo, of complex formation 
between immunodominant HEL peptides and I-A  k molecules, preventing I-AL-restricted T cell 
induction. Administration of ML46-62 after antigen priming does not affect ongoing antibody 
responses, as expected from MHC blockade. A single injection of ML46-62 at the time of protein 
antigen priming precludes not only the primary, but also the secondary antibody response to 
a subsequent challenge with soluble protein, even when the challenge is performed several months 
after priming. Coinjection of antigen and MHC antagonist inhibits production of all antibody 
isotypes equally well, suggesting that MHC class II blockade affects both Thl- and Th2-type 
T  helper cells. Therefore, these results  indicate that administration of MHC class II-binding 
peptides can efficiently and selectively prevent the induction of T cell-dependent primary and 
secondary in vivo antibody responses  by blocking antigen presentation to class II-restricted 
T  helper cells. 
p ~eptides bound to class II MHC molecules on the surface 
of APCs are the ligands for antigen-specific receptors of 
CD4 + T  cells (1). Each MHC class II molecule can bind 
different peptides, indicating that the interaction between pep- 
tides and class II molecules exhibits a low degree of selec- 
tivity (2). One consequence of the broad-range specificity 
ofpeptide-MHC interactions is that peptides of different se- 
quences may compete for presentation by the same MHC 
molecule to T  lymphocytes. 
Peptide competition for antigen presentation has  been 
demonstrated in vitro, by showing that antigens binding to 
the same MHC molecules can compete with each other for 
presentation to T cells (3-6). A direct correlation has been 
demonstrated between the capacity of a peptide to bind to 
purified MHC class II molecules and its ability to compete 
for presentation of antigenic peptides binding to the same 
class II molecules (7, 8). Peptide competition for the MHC 
class II binding site also occurs in vivo. This has been demon- 
strated first by competition between self- and non-self pep- 
tides for T cell activation, showing that T cell responses to 
antigenic peptides can be inhibited by coinjection of antigen 
and an unrelated MHC class II-binding competitor peptide 
(9). Subsequently, several groups have used a similar strategy 
to prevent induction of T cell-mediated autoimmune  diseases 
like experimental allergic encephalomyelitis in mice (10, 11) 
and rats (12), or autoimmune carditis  in mice (13). 
These results suggest that in vivo competition for antigen 
presentation may result in MHC blockade preventing T cell 
activation. Recently, using an ex vivo system, we have demon- 
strated that lymph node cells (LNC) 1 from mice immunized 
1 Abbreviations  used in  this lsa~r:  HEL, hen egg-white lysozyme; LNC, 
lymph node cells; RNase, bovine ribonuclease. 
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antigenic peptide-class II complexes able to stimulate, in the 
absence of any further antigen addition, HEL peptide-specific, 
class II-restricted T cell hybridomas. Coadministration of an- 
tigen and MHC class II-binding peptide competitors selec- 
tively inhibits the in vivo formation of antigenic complexes 
and prevents antigen presentation by LNC to class II-restricted 
T cells, indicating competitive blockade of class II molecules 
in vivo (14). MHC class II blockade can be induced by ad- 
ministering MHC antagonists either in a depot (9,  14, 15) 
or in soluble form (16), and this could represent a promising 
approach to selectively  induce immunosuppression of  undesired 
immune responses (17). However, several points still need to 
be addressed to evaluate the practical feasibility of this form 
of immunointervention. 
In the present paper we have examined the effect of MHC 
dass II blockade on the in vivo antibody responses to T cell-de- 
pendent antigens. Injection of a nonimmunogenic MHC class 
II-binding self-peptide  at the time of antigen priming can 
inhibit both primary and secondary antibody responses  to 
protein antigens. This inhibition is associated with decreased 
formation of antigenic peptide-MHC class II complexes  in 
vivo, resulting in inhibition of class II-restricted T cell prolifer- 
ation. All antibody isotypes are equally inhibited, suggesting 
that MHC blockade inhibits activation of  both Thl- and Th2- 
type T  helper cells. As for T  cell activation, the inhibition 
of antibody responses is selective for the MHC class II mole- 
cules binding the competitor peptide, and its extent depends 
on the molar ratio between antigen and competitor. 
Materials and Methods 
Mice.  2- to 3-mo-old DBA/2,  BALB/c, C3H, B10.D2 (Iffa 
Credo, L'Arbesle,  France) and B10.A(4R) (Olaco Bicester, UK) mice 
of either sex were used. 
Antigens.  HEL, recrystallized  three times, and bovine RNase 
were obtained from Sigma Chemical Co. (St. Louis, MO). Peptides 
were synthesized by the solid-phase method on phenylacetamido- 
methyl-polystyrene support using side chain protection, coupling 
procedures, and an automated apparatus (model 430A; Applied Bio- 
systems, Inc., Foster City, CA) as described (9). Crude peptides 
were purified  by preparative HPLC on a C18 reverse-phase  column. 
The peptides showed correct amino acid ratios upon hydrolysis  in 
6 N HC1 and the expected molecular ions in fast atom bombard- 
ment mass spectrometry. Sequences were confirmed by gas-phase 
microsequencing. 
Immunizations.  Mice  were immunized subcutaneously at the 
taft base and into the hind footpads, or by intraperitoneal injection 
with the indicated amount of antigen emulsified in IFA or CFA 
containing H37Ra mycobacteria  (Difco  Laboratories, Inc., Detroit, 
MI). For the induction of secondary  antibody responses, mice were 
challenged  by injecting intraperitoneally 100/zg/mouse of soluble 
antigen in PBS. 
ELISA.  Polyvinyl  microtiter plates (Falcon  model 3012; Becton 
Dickinson & Co., Oxnard, CA) were incubated overnight at 4~ 
with 50/~l/well of HEL or RNase at 10/~g/ml in 60 mM sodium 
carbonate-bicarbonate buffer, pH 9.6. After washing with PBS, 
the plates were blocked by incubation with PBS containing 1% 
BSA for 1 h at 37~  Plates were then washed three times with 
PBS containing 0.1% Tween 20 (PBS-Tw). Appropriately diluted 
sera (50 td/well) were titrated in PBS-Tw  containing  1% BSA (PBSA- 
Tw), and incubated for 90 min at 37~  Plates were then washed 
and incubated for 1 h at 37~  with a mixture (100 ng/ml each) 
of the following  biotin-conjugated  goat anti-mouse isotype-specific 
antibodies (Southern Biotechnology Associates Inc., Birmingham, 
AL): anti-IgM, -IgG1, -IgG2a, -IgG2b, and -IgG3. After washing, 
the bound antiisotypic antibodies were revealed by an additional 
1-h incubation with alkaline  phosphatase-conjugated streptavidin 
(Jackson Immunoresearch Laboratories, Inc., West Grove, PA) 
diluted 1:20,000. The plates were washed again and incubated with 
the developing  substrate  p-Nitrophenylphosphate  disodium (Sigma 
Chemical Co.) in diethanolamine  buffer,  pH 9.6 (100 ttl/well). The 
reaction was stopped by adding 50/~l/well NaOH 3 N, and absor- 
bance was read at 405 nm using an automated microplate ELISA 
reader (Titertek Multiskan  |  MCC/340; Flow Laboratories, Hel- 
sinki, Finland). Standard curves were generated using pooled sera 
from mice immunized  with the corresponding  antigen. The amount 
of  HEbspecific  antibodies  was calculated  using affinity-purified  anti- 
HEL antibodies and results expressed as serum antibody concen- 
tration in mg/ml. The serum anti-RNase antibody concentration 
was expressed as arbitrary  U/ml. Anti-HEL and -RNase IgM, lgG1, 
IgG2a, IgG2b isotypes were determined as described above using 
biotinylated isotype-specific  antibodies. Standard curves were ob- 
tained using calibrated serum pools revealed  with antiisotypic de- 
veloping reagents, and results expressed as relative U/ml. 
T Cell Proliferation  Assay.  LNs draining the injection sites were 
removed, and 4  x  10  s cells/well were cultured in 96-well culture 
plates (Costar Corp., Cambridge, MA) in synthetic HL-1 medium 
(Ventrex Laboratories, Portland, ME) supplemented with 2 mM 
L-glutamine  and 50 ttg/ml gentamicin (Sigma Chemical Co.) with 
the indicated antigen concentrations. Cultures were incubated for 
3 d in  a humidified atmosphere of 5%  CO2 in  air and were 
pulsed 10 h before harvesting with 1/~Ci [3H]TdR (40 Ci/nmol; 
the  Radiochemical Center, Amersham, UK).  Incorporation of 
[3H]TdR was measured by liquid scintillation spectrometry. 
Assay for Antigen Presenting Activity of LNC from HELprimed 
Mice.  The antigen presenting activity of LNC from HEL-primed 
mice was assessed as previously  described (14) using the following 
T cell hybridomas: 1C5.1 (I-A  k, HEL46-61) (14); 3Bl1.1 (I-A  k, 
HEL34-45) (Adorini, L., unpublished results); and 1Hll.3 (I-E  a, 
HELl08-116) (8). Briefly, mice were immunized into  the hind 
footpads with the indicated amount of antigen emulsified  in IFA 
or CFA. 5-6 d later, the draining popliteal LNC were removed, 
irradiated (2,400 tad), and cultured in triplicate at the indicated 
cell doses with appropriate HElcspecific  T cell hybridomas (5  x 
104 cells/well) in 96-well culture plates (Costar Corp.). Culture 
medium was RPMI 1640 (Gibco, Basel, Switzerland)  supplemented 
with 2 mM t-glutamine,  50 mM 2-ME, 50/zg/ml gentamicin 
(Sigma Chemical Co.), and 10% FCS (Gibco). After 24 h of cul- 
ture, 50-/~1 aliquots of supernatants were transferred to microcul- 
ture wells containing 104 CTLL cells and, after an additional 24-h 
incubation, the presence of T cell growth factors, mainly IL-2, was 
assessed by [3H]TdR incorporation during the last 4 h of culture. 
For the anti-Thy-1 cytotoxic treatment, LNC (6  x  106/ml) were 
incubated with 1.5/~g/ml of anti-Thy-l.2 mAb (Becton Dickinson 
& Co., Mountain View, CA) for 30 min on ice. After washing, 
cells were resuspended  in rabbit complement (low-tox M|  Cedar- 
lane Laboratories, London, Canada) at a final  dilution of 1:12, in- 
cubated 45 rain at 37~  washed, and then irradiated. T cell deple- 
tion was assessed by cytofluorimetric analysis with biotinylated 
anti-TCR mAb (18). 
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ML 46-62 Inhibits the Anti-HEL Antibody Response in H-2 ~ 
but Not in 1-1-2  d Mice.  The mouse lysozyme (ML) peptide 
46-62  binds strongly to I-A  k molecules but fails to bind to 
I-E  k, I-A  a, and I-E  d molecules (5, 9, 16). We have previously 
shown that administration of this peptide selectively blocks, 
in vivo, T cell activation induced by I-ALbinding antigenic 
peptides  (9,  14). To  examine the effect  of MHC  class II 
blockade on T cell-dependent antibody responses, B10.A(4R) 
mice, expressing only the I-A  k class II molecule, were im- 
munized intraperitoneally with HEL (35 pmoles/mouse) alone, 
or mixed with either 5 or 0.5 nmoles of ML46-62. The anti- 
HEL antibody response was quantitated by ELISA at different 
times after priming. As shown in Fig.  1 A, administration 
of ML46-62 (5 or 0.5 nmoles/mouse) inhibits almost com- 
pletely the anti-HEL antibody response. The inhibitory effect 
was slightly reduced at 14-fold competitor excess over HEL, 
as compared with 140-fold excess. As expected from its binding 
specificity,  ML46-62  administered  at  5  nmoles/mouse  to 
DBA/2 (H-2  d) mice does not affect the anti-HEL antibody 
response (Fig.  1 B), demonstrating that this peptide is de- 
void of any nonspecific immunosuppressive properties. There- 
fore, as for T cell priming in vivo, inhibition of the antibody 
response by administration of class II-binding competitor pep- 
tides is selective for the MHC class II molecules to which 
the competitor binds, and its extent depends on the molar 
ratio between antigen and competitor. 
Inhibition of the Primary and Secondary Antibody Response to 
HEL and RNase, an Antigen  Unrelated to the MHC Blocker, 
Having shown that ML46-62 is able to selectively block the 
primary anti-HEL antibody response in B10.A(4R) mice, we 
tested its ability to inhibit both primary and secondary anti- 
body responses  to HEL and to KNase, an antigen unrelated 
to ML46-62. As shown in Fig.  2, ML46-62 administration 
induces a 5-10-fold reduction of the primary antibody re- 
sponses to both protein antigens. This inhibition is long-lasting 
and can be observed over a period of 20 wk. Upon challenge 
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Figure  1.  Inhibition  of the primary  anti-HEL  antibody  response  by ad- 
ministration of ML46-62. B10.A(4R) (.4) or DBA/2 (B) mice were im- 
munized intraperitoneally  with CFA only (A) or with an emulsion  con- 
taining 35 pmoles HEL alone (O), or mixed with 5 nmoles (0) or 0.5 
nmoles (A) of ML46-62. The anti-HEL  antibody  response was measured 
by quantitative  ELISA  in individual  mice  at the indicated  days  after  priming 
by ELISA.  Data are expressed as mean + SEM anti-HEL  serum antibody 
concentration (mg/ml) from three to four mice per group. 
with the corresponding soluble protein antigens, a 20-fold 
increase of antigen-specific  serum antibody is induced, but 
in mice injected with ML46-62 at the time of priming, the 
secondary antibody response was 10-20-fold lower than control 
responses.  This effect  is  specific since  administration of a 
non-I-ALbinding peptide (HEL64-77) does not affect the 
anti-HEL (Fig.  2 A) or the anti-RNase (data not shown) 
antibody responses.  In Fig. 2 B, the competitor peptide was 
administered in IFA 1 d before immunization with KNase, 
indicating that separate administration of antigen and com- 
petitor also inhibits primary and secondary antibody responses. 
The results indicate that administration of class II-binding 
competitor peptides unrelated to the antigen can efficiently 
inhibit both primary and secondary in vivo antibody responses 
induced by Th whose activation is restricted by the blocked 
class II molecule. 
Effect of MHC Blockade on Anti-HEL  and Anti-RNase Ig 
lsotypes.  The inhibitory effect of ML46-62 was tested, so 
far, by measuring the whole humoral response. We next de- 
termined whether different antigen-specific  Ig isotypes were 
all similarly affected.  Results in Table 1 show that, in the 
primary and secondary anti-HEL antibody responses,  IgG1 
is the dominant isotype, and that all Ig isotypes measured 
are inhibited by administration of ML46-62. Conversely, in- 
jection of HEL64-77 does not significantly affect any of the 
antioHEL Ig isotypes. This inhibition is more pronounced 
in the secondary response,  and it is higher for the dominant 
isotype. Similar results are obtained measuring anti-RNase 
Ig isotypes. In this case, unlike HEL, the primary antibody 
response also includes IgM antibodies. In the primary response, 
IgG1 and IgM are predominantly reduced, whereas in the 
secondary response,  all isotypes are inhibited. Collectively, 
these results indicate that inhibition of antibody response by 
MHC class II blockade affects all Ig isotypes.  Since IgG1 are 
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Figure 2.  Inhibition  of primary  and secondary  anti-HEL  and anti-RNase 
antibody responses by administration  of ML46-62. (A) B10.A(4R) mice 
were immunized  intraperitoneally  with 35 pmoles  HEL alone  (O), or mixed 
with either ML46-62 (Q) or HEL64-77 (A), (5 nmoles/mouse).  (B) Mice 
were injected 1 d before antigen priming with IFA alone (O) or with 
30 nmoles ML46-62 (Q) in IFA, and then immunized  with RNase, 210 
pmoles/mouse  in CFA. Mice  were  then  challenged  with the corresponding 
soluble antigen  (100/zg/mouse)  about 20 wk after  priming  (arrows).  Results 
are expressed as mean anti-HEL antibody  concentration (mg/ml) from 
three to four mice per group, or as mean _+ SEM anti-RNase antibody 
serum concentration  expressed  in arbitrary  mU/ml  from  six mice  per group. 
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Serum antibody concentration 
Antigen  Competitor  Challenge  Ig M  IgG1  IgG2a  IgG2b 
HEL  -  -  <5  1,915  +_  318  34  •  29  196  •  101 
HEL  ML46-62  -  <5  153  _+  91  5  •  3.2  11.3  _+  6.6 
HEL  HEL64-77  -  <5  1,762  •  722  9.1  •  4.5  119  _+  18 
HEL  -  HEL  <5  14,840  •  6,162  291  •  199  874  _+  507 
HEL  ML46-62  HEL  <5  724  +_  125  42  _+  24  92  _+  63 
HEL  HEL64-77  HEL  <5  10,237  •  4,004  171  •  122  1,175  •  597 
RNase  -  -  13.5  •  5.8  1,169  _+  231  117  •  45  196  •  71 
RNase  ML46-62  -  5.3  •  2.2  335  _+  110  83  •  19  151  +  43 
R.Nase  -  RNase  <5  14,534  +  6,212  1,443  •  568  1,908  •  629 
RNase  ML46-62  KNase  <5  627  •  224  316  _+  142  554  _+  329 
Sera from the experiment described in Fig. 2 were tested for anti-HEL and anti-RNase lg isotypes by ELISA, as described in Materials and Methods. 
Results shown refer to antibody isotypes detected in sera obtained at peak primary (day 31 for HEL, day 43 for RNase) and secondary (day 9 for 
HEL, day 21 for RNase) antibody responses. Results are expressed as serum antibody concentration (U/ml)  _+ SEM from three to five mice per group. 
predominantly  induced  by Th2  and IgG2a/IgG2b by Thl 
cells (19-21),  MHC  blockade appears to inhibit  the  helper 
function  of both  Th  cell  subsets. 
Lack of  Inhibition of  Anti-HEL Antibody Response by Adminis- 
tration of ML46-62  in Primed Mice,  We  next  analyzed  the 
effect of administering  ML46-62  1 d  before immunization 
or  10  d  after priming  with  HEL.  As  shown  in  Fig.  3  (D 
and E), administration to B.10A(4R) mice of the competitor 
peptide emulsified together with HEL, or in a separate depot 
1 d  before HEL priming,  strongly inhibits  the entire  anti- 
HEL antibody response, as compared with controls (Fig.  3, 
A  and B). Conversely, ML46-62 administered 10 d after HEL- 
CFA priming does  not  affect the  ongoing  anti-HEL  anti- 
body response (Fig. 3 F). Similar results were obtained when 
ML46-62 was administered 3 d after HEL priming (data not 
shown).  These results confirm that the coadministration  of 
antigen  and competitor  is not  a prerequisite  for inhibition 
of the antibody response,  as previously shown with RNase 
(Fig.  2 B).  It is interesting  that once the immune response 
is initiated, the competitor peptide has no effect, a result con- 
sistent  with  the  MHC  blockade  model. 
Direct Evidence  for MHC Blockade Induced In Vivo by ML46- 
62.  To analyze the mechanisms involved in MHC blockade, 
we recently described an ex vivo system to detect complexes 
between antigenic peptides and MHC class II molecules gener- 
ated  in vivo (14).  Using  this  assay we tested  the ability of 
ML46-62 to selectively inhibit in vivo formation of antigenic 
complexes  between  I-A  k  class  II  molecules  and  the  two 
dominant HEL peptides 46-61 and 34-45 derived from HEL 
processing  (22).  H-2  k  (C3H  and  B10.A[4R])  and  H-2  a 
(BALB/c and B10.D2)  mice were immunized with HEL or 
with  an emulsion containing  HEL and  ML46-62  either  in 
IFA or in  CFA.  5  d  later,  irradiated  LNC  were  tested  for 
their ability to activate the l-Ak-restricted T  cell hybridomas 
1C5.1  (HEL46-61/A k)  and  3Bl1.1  (HEL34-45/A k)  or  the 
I-Ed-restricted T  cell hybridoma  1Hll.3  (HEL108-116/Ed). 
As shown in Fig. 4, coinjection of HEL and the I-Ak-bind  - 
ing peptide ML46-62 markedly inhibits the antigen presenting 
activity  of LN  APC  to  the  I-Ak-restricted  T  cell  hybrid- 
omas,  specific for HEL peptides  46-61  and  34-45,  in both 
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Figure  3.  Lack  of inhibition of the anti-HEL antibody response by ad- 
ministration of ML46-62 to primed mice. B10.A(4R) mice were injected 
with IFA alone or with ML46-62 (5 nmoles/mouse) in IFA, 1 d before 
(A and D) or 10 d after (C and F) immunization with 35 pmoles/mouse 
HEL/CFA.  (B and E) Mice were immunized in CFA with I-IEL alone 
(B) or mixed with 5 nmoles/mouse ML46-62 (E). Results are expressed 
as anti-HEL serum antibody concentration (mg/ml) from three to four 
individual mice per group. 
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Figure 4.  Selective  inhibition of l-ALrestricted antigen 
presentation by ML46-62. BIO.A(4R) (.4 and D), C3H (B 
and E), and BALB/c  (C) mice  were immunized  in IFA with 
3 nmoles HEL alone (O) or mixed with 100 nmoles MIA6- 
62 (O). 5 d later, LNC from three mice  were  pooled, irradi- 
ated and cultured with the T cell hybridomas  3Bl1.1 (.4 and 
B), 1C5.1 (D and E), or 1Hll.3 (C). After 24 h, II.-2  produc- 
tion was measured  by adding 50 #1 aliquots of  culture super- 
natant to 104 CTLL for an additional 24 h. [3H]Thymidine 
(1 #Ci/well) was added during the last 5 h of culture. I1.-2 
production induced in T cell bybridomas  by addition of 3 
/~M HEL to 2.5  x  10  s LNC/well from mice injected with 
HEL alone  or mixed  with the competitor  peptide  were  respec- 
tively (cpm): 117,031, 129,413 (,4); 128,927, 95,432 (B); 
211,492, 218,803 (C); 105,126, 87,499 (D); and 100,203, 
118,098 (E). Data are presented as mean cpm of thymidine 
incorporation  from triplicate  cultures. Background  prolifera- 
tion of CTLL cells was 258 cpm. 
B10.A(4R) and C3H mice. Conversely, coinjection of ML46- 
62,  nonbinding to I-E  a molecules, does not affect the an- 
tigen  presenting  activity of LNC  from  BALB/c  mice  to 
the bEe-restricted, HEL108-116-specific, T  cell hybridoma 
1Hll.3. In addition, the ability of LN APC from compet- 
itor peptide-injected mice to process and present exogenous 
HEL added in vitro is not modified (see legend to Fig.  4). 
To eliminate the possibility that inhibition of T  cell hy- 
bridoma activation could be due to suppressor T cells induced 
by ML46-62 in the LNC population, T  cell-depleted LNC 
from B10.A(4R) or B10.D2 mice immunized with HEL in 
CFA alone or mixed with ML46-62 were used as APC. Results 
in  Fig.  5  show  that  the  antigen presenting  activity of T 
cell-depleted APC  from HEL-primed B10.A(4R)  mice to 
both I-Ak-restricted T cell hybridomas is strongly decreased 
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Figure 5.  Inhibition of antigen presentation is not due to T cells. 
B10.A(4R) (A, B) and B10.D2 (C) mice  were  immunized  with CFA con- 
taining 3 nmoles HEL alone  (I-I) or mixed  either  with 100 nmoles  ML46- 
62 (m) or 100 nmoles HEL64-77 (E~). 5 d later, LNC from two mice 
were pooled, treated with anti-Thy-1 mAb plus C', irradiated, and 106 
cells/well cultured with the T cell hybridomas: 3Bl1.1 (ti), 1C5.1 (B), 
and 1Hll.3 (D). The experiment  was then continued  as in Fig. 4. Data 
are shown as mean (cpm) _+ SEM from triplicate cultures. Background 
proliferation of CTLL was 545 cpm. 
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by coadministration of the I-Ak-binding competitor peptide, 
but not by the nonbinding peptide HEL64-77. The specificity 
of the inhibitory effect is indicated by lack of inhibition, after 
injection of the same  emulsion in B10.D2 (H-2  d) mice, of 
the I-Ea-restricted presentation to the HEL108-116-specific 
T  cell hybridoma 1Hll.3.  Therefore, these results demon- 
strate that inhibition of T cell hybridoma activation is selec- 
tive for the MHC molecule to which the competitor peptide 
binds, and it does not depend on the presence of LN T cells, 
ruling out a possible role for suppressor T  cells. 
To correlate the inhibition of antigen presentation with 
the inhibition of T  cell proliferation, C3H mice were im- 
munized with  HEL alone in  CFA,  or mixed with either 
ML46-62 or HEL64-77. 6 d later, the same LNC population 
was simultaneously tested for antigen presentation to both 
I-Ak-restricted T cell hybridomas 1C5.1 and 3Bl1.1, and for 
T cell proliferation to I-E  k- or I-Ak-restricted HEL peptides. 
As shown in Fig. 6, A  and B, coadministration of a 16-fold 
excess of ML46-62 strongly decreases the antigen presenting 
activity of LN APC to both I-Ak-restricted T  cell hybrid- 
omas, whereas, as shown previously, no inhibition is induced 
by  the  non-I-Ak-binding  peptide  HEL64-77.  The  same 
LNC  populations  were  tested  for  T  cell proliferation  to 
four immunodominant HEL peptides. Results demonstrate 
that the proliferative response of T  cells  from mice coim- 
munized with HEL and ML46-62 to the I-Ak-binding pep- 
tides 46-61, 51-61, and 112-129 is inhibited as compared with 
control groups (Fig.  6, D-F), whereas no effect is observed 
on the T cell proliferation recalled by the I-Ek-binding pep- 
tide HELl-18 (Fig. 6 C). Taken together, these results dem- 
onstrate that administration of the class II-binding peptide 
ML46-62  inhibits  I-Ak-restricted antigen  presentation  to 
T  cell hybridomas and antigen-specific proliferation of bulk 
T  cells, indicating I-A  k blockade by the competitor peptide. O 
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Figure  6.  Inhibition of HEL peptides-I-A  k complex formation corre- 
lates with inhibition of I-Ak-restricted  T  cell proliferation.  C3H mice 
were immunized in CFA with 3 nmoles HEL alone (O) or mixed either 
with 50 nmoles  HEL64-77  (A) or 50 nmoles  ML46-62  (I).  6 d later, 
LNC from two mice were pooled, and either irradiated and cultured with 
the T cell hybridomas  1C5.1 (.4) or 3Bl1.1 (B), or restimulated  in vitro 
with the indicated concentration of HELl-18 (C), HEL46-61 (D), HEL51-61 
(E), and HELl12-129  (F). (A and B) Results  are expressed as in Fig. 4. 
(C-F), after 3 d of culture,  1/~Ci [3H]thymidine/well  was added,  and 
cells harvested 10 h later. Data are presented as mean A cpm from dupli- 
cate cultures. Backgrounds (no antigen) cpm were 12,379 (O), 8,970 (A), 
and  10,696 (O). 
Discussion 
Induction of immunosuppression by MHC class II antag- 
onists has been demonstrated in a variety of experimental 
systems, by examining their effect on T  cell activation, in 
vivo,  either in response to conventional antigens (9)  or in 
autoimmune disease models (10--13). However, MHC blockade 
has been evaluated mostly by its effect on T  cell prolifera- 
tion,  and this may not reflect the entire immune response 
(23). Therefore, we have examined the effect of administering 
a class II-binding peptide on induction of T cell-dependent 
antibody responses to protein antigens. 
The mouse self-lysozyme peptide ML46-62 binds to I-A  k 
molecules (5,  9,  16) and it sdectively inhibits, when coin- 
jected with  antigen,  priming  of I-Ak-restricted,  antigen- 
specific T  cells (9).  We have coinjected ML46-62 together 
with protein antigens, HEL or RNase, in B10.A(4K) mice, 
expressing only I-A  k as MHC class II molecules. Therefore, 
in this mouse strain, the T cell-dependent antibody response 
to protein antigens such as HEL or RNase can only be medi- 
ated by I-Ak-restricted T  helper cells. In the case of HEL, 
different immunodominant T cell epitopes generated by HEL 
processing are presented by I-A  k molecules.  Three major im- 
munodominant HEL determinants recognized by I-Ak-re  - 
stricted T cells are included in the HEL sequences 46-61 (22), 
34-45 (22, 24), and 112-129 (25), and a minor one is located 
in the HEL region 25-43 (25).  In the case of RNase, an im- 
munodominant epitope able to induce I-Ak-restricted T cells 
is located in the region 43-56 (26).  Since all these epitopes 
are potentially able to induce T  helper cells, blocking the 
antigen-presenting function of the I-A  k molecule should re- 
sult in inhibition of the antiprotein antibody response only 
ifT cell responses to all these determinants are blocked. Results 
in the present paper demonstrate that this is the case: coin- 
jection of ML46-62  and HEL in B10.A(4R) mice inhibits 
the entire anti-HEL antibody response. Similarly, coinjection 
of ML46-62 and KNase, an antigen unrelated to this class 
II-binding peptide, results in inhibition of the entire anti- 
RNase antibody response. 
Administration of class II-binding peptides could inhibit 
in vivo T  cell activation by antigen (23,  27-32)  or MHC- 
related mechanisms (10, 11, 13, 14). Several lines of evidence 
indicate that the mechanism leading to inhibition of T cell-de- 
pendent antibody responses by administration of ML46-62 
is in vivo blockade of MHC class II molecules and a conse- 
quent decrease in antigen-specific T cell responses.  First, this 
self-peptide does not activate mouse T cells (9), therefore a 
direct blockade of T  cell receptors by ML46-62 is unlikely￿9 
Second, since ML46-62 does not induce a T  cell response, 
the inhibition of antibody production cannot be attributed 
to clonal dominance induced by the competitor peptide. Third, 
ML46-62 inhibits efficiently the antibody response induced 
by RNase, an unrelated protein antigen, indicating that in- 
hibition of the antibody response does not result from in- 
duction of T cell tolerance or antigen-specific suppressor T 
cells. Fourth, injection of ML46-62 selectively inhibits anti- 
body responses induced by T helper cells restricted by I-A  t, 
as expected from its binding specificity (5, 9,  16), thus ex- 
cluding a possible induction of nonspecific suppressive mech- 
anisms.  Finally,  administration  of ML46-62  after antigen 
priming does not inhibit  the ongoing antibody response, 
demonstrating its capacity to prevent T cell activation when 
coinjected with antigen, but not when injected subsequently, 
as predicted from the MHC blockade model. 
MHC blockade as the mechanism leading to inhibition 
of antibody responses in vivo is also indicated by the con- 
comitant in vivo inhibition of complexes formed between 
peptides derived from antigen processing and class II mole- 
cules. In addition to the 46-61 epitope (14), the most abun- 
dant naturally processed HEL epitope bound to I-A  k mole- 
cules (33),  HEL34-45-I-A k complexes formed in vivo are 
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of both epitopes, we have demonstrated that administration 
of ML46-62  selectively inhibits the capacity of I-A  k mole- 
cules to present antigen to T cells. Inhibition of antigen pre- 
sentation is associated with inhibition of I-Ak-restricted T 
cell proliferation to all immunodominant HEL epitopes tested, 
demonstrating the functional role of MHC blockade. Thus, 
inhibition of T cell-dependent antibody responses by adminis- 
tration of ML46-62 correlates with inhibition of antigenic 
complex formation in vivo and with inhibition of T  cell 
priming, indicating MHC blockade as the mechanism leading 
to inhibition of antibody responses in vivo. This was previ- 
ously postulated in a transgenic model where autoantibody 
production against the neo-self  hepatitis B e antigen (HBeAg) 
was induced by a nontolerogenic T  cell epitope of HBeAg 
and inhibited upon coadministration of an unrelated exoge- 
nous peptide (34). 
Two types of T helper cells, Thl and Th2, have been de- 
scribed in the mouse, based on their different lymphokine 
production pattern (35). Thl cells, which produce IL-2 and 
IFN-3,, preferentially induce synthesis of antibodies expressing 
the IgG2a isotype. Conversely, Th2 cells, producing IL-4, 
-5, and -10, mainly elicit antibody responses oflgG1 and IgE 
isotype and cause B cell proliferation and differentiation (19-21, 
36). Based on the fact that IgG1 and IgG2a/IgG2b isotypes 
were inhibited, as well as T cell proliferative responses, it is 
likely that MHC blockade inhibits activation of Thl-  and 
Th2-type helper cells equally well. Therefore, the inhibition 
of clonal expansion of Th cells by blocking the initial an- 
tigen-TCR interaction seems to affect both types of Th cells, 
preventing B cell proliferation and differentiation as well as 
generation of antigen-specific memory cells. This is exemplified 
by the inhibition of the secondary immune response where 
the unresponsiveness in B cells to soluble antigen is likely 
to arise both from lack of antigen-specific T cell help, mainly 
of Th2-type, and lack of antigen-specific memory B cells able 
to endocytose soluble antigen and to present efficiently anti- 
genic peptide-MHC  complexes to primed T  cells  (37). 
Tolerance induction by antigens administered in nonim- 
munogenic form can also inhibit T  cell activation in vivo. 
It has been recently shown that antigen-specific unrespon- 
siveness induced by pretreatment with aqueous antigen selec- 
tively tolerizes Thl-like but not Th2-1ike  T  cells (38, 39). 
Since human CD4 + T cell clones specific for allergenic and 
helmintic antigens, exhibit Th2-1ike lymphokine production 
profile (40), in these cases tolerance induction may not affect 
pathogenic T  cells.  Conversely, as discussed above,  MHC 
blockade can effectively inhibit the helper function of both 
Thl- and Th2-type cells. 
In conclusion, we have demonstrated that administration 
of MHC class II antagonists can inhibit the induction of T 
cell-dependent primary and secondary antibody responses. 
Inhibition of in vivo antibody responses is associated to preven- 
tion of complex formation between antigenic peptides and 
class II molecules indicating MHC blockade as the mecha- 
nism hindering T  helper cell activation.  Therefore, MHC 
class II antagonists may induce selective immunosuppression 
in HLA-associated autoimmune diseases (17), including dis- 
eases, like myasthenia gravis, where autoantibodies have a di- 
rect pathogenic role (41). 
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